SINDROME DE PIERNAS INQUIETAS: NOVEDADES EN EL DIAGNOSTICO Y EL TRATAMIENTO





SINDROME DE PIERNAS INQUIETAS: NOVEDADES EN EL DIAGNOSTICO Y EL TRATAMIENTO

(especial para SIIC © Derechos reservados)
Las distintas alternativas terapéuticas para tratar el síndrome de las piernas inquietas, incluidos los agentes dopaminérgicos, debe ser considerada en cada caso particular, en función de la gravedad de los síntomas y del perfil de efectos adversos.
chik9.jpg Autor:
Yolanda Chik
Columnista Experto de SIIC

Institución:
Johns Hopkins School of Medicine


Artículos publicados por Yolanda Chik
Coautores
Rachel Salas* Charlene Gamaldo* 
MD, Johns Hopkins School of Medicine, Baltimore, EE.UU.*
Recepción del artículo
30 de Septiembre, 2009
Aprobación
25 de Febrero, 2010
Primera edición
22 de Junio, 2010
Segunda edición, ampliada y corregida
7 de Junio, 2021

Resumen
El síndrome de las piernas inquietas (SPI) es una enfermedad sensitivomotora frecuente que se asocia en general con alteraciones significativas del sueño y con molestias durante la vigilia, que potencialmente pueden incrementar el riesgo de comorbilidades. El SPI se diagnostica cuando se cumplen los siguientes cuatro criterios: la necesidad de movimiento, habitualmente en asociación con parestesias; inicio o exacerbación de los síntomas durante el descanso; alivio de los síntomas con el movimiento, y síntomas que se manifiestan con un ritmo circadiano. El SPI puede presentarse en adultos y niños y existe una predisposición genética vinculada con una presentación más temprana de los síntomas de la enfermedad, en general antes de los 45 años. Una variedad de trastornos pueden asemejarse al SPI, por lo cual es importante el diagnóstico diferencial durante la evaluación del paciente. El tratamiento del SPI incluye el suplemento de hierro, agentes dopaminérgicos (AD), opioides, benzodiazepinas y fármacos antiepilépticos. Los AD se asocian con un mayor efecto terapéutico y dos fármacos de este grupo son los únicos medicamentos aprobados por la FDA para el tratamiento del SPI en EE.UU. El suplemento de hierro en los pacientes con SPI puede ser de utilidad cuando se trata de enfermos con deficiencia de este mineral. Sin embargo, cada una de las alternativas terapéuticas, incluidos los AD, debe ser considerada en cada caso particular, en función de la gravedad de los síntomas y del perfil de los efectos adversos. La mayor identificación y el enfoque del SPI, un trastorno a menudo debilitante, puede asociarse con una mejoría en la calidad de vida y la potencial optimización de la salud en general para las muchas personas que lo padecen.

Palabras clave
síndrome de piernas inquietas, dopamina, epidemiología, tratamiento, diagnóstico, síndrome de piernas inquietas, movimientos periódicos de las piernas, diagnóstico, tratamiento, aceleración, dopamina


Artículo completo

(castellano)
Extensión:  +/-15.26 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

Abstract
Restless legs syndrome (RLS) is a common sensorimotor disorder that is usually associated with significant sleep disturbance and daytime complaints potentially leading to increased co-morbid health risks. RLS is diagnosed by fulfilling the following four criteria: (1) an urge to move, usually associated with paresthesias, (2) onset or exacerbation of symptoms at rest, (3) relief of symptoms with movement, and (4) symptoms manifest in a circadian pattern. Adults and children can suffer from RLS and there is a genetic predisposition manifesting with an earlier age of onset of RLS symptoms, usually before the age of 45 years. A variety of conditions may mimic RLS so it is important to differentiate these during evaluation of the patient. Treatment of RLS includes iron supplementation, dopaminergic agents (DA), opioids, benzodiazepines, and anti-epileptic drugs (AEDs). DA demonstrate the largest treatment effect and include the only two FDA approved in the United States to treat RLS. Iron supplementation in RLS patients who are found to be iron deficient may be beneficial as well. However, each of the treatment options, including the use of DA, must be considered on a case-by-case basis taking into account symptom severity and side effect profiles. Increased recognition and management of RLS, an often debilitating condition, can lead to an improved quality-of-life and potentially improved overall health for the many who suffer from RLS.

Key words
restless legs syndrome, restless legs syndrome, periodic legs movement, dopamine, diagnosis, epidemiology, treatment, treatment, augmentation, diagnosis, dopamine


Full text
(english)
para suscriptores/ assinantes

Clasificación en siicsalud
Artículos originales > Expertos del Mundo >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Neurología
Relacionadas: Atención Primaria, Educación Médica, Farmacología, Geriatría, Medicina Familiar, Medicina Interna, Pediatría



Comprar este artículo
Extensión: 15.26 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
Yolanda Chik, Johns Hopkins School of Medicine Department of Neurology, MD 21205, 600 North Wolfe St., Baltimore, EE.UU.
Bibliografía del artículo


1. Walters AS. The International Restless Legs Syndrome Study Group: Toward a better definition of the restless legs syndrome. Mov Disorders 10:634-42, 1995.
2. Hening W, Montplaisir J, Walters A, et al. Impact of restless leg syndrome (RLS) on sleep: the REST (RLS epidemiology, symptoms and treatment) Study in Primary Care. Sleep 26:A332, 2003.
3. Hening W, Walters AS, Allen RP, et al. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med 5:237-246, 2004.
4. Hogl B, Kiechl S, Willeit J, et al. Restless legs syndrome: a community-based study of prevalence, severity, and risk factors. Neurology 64:1920-1924, 2005.
5. Bjorvatn B, Leissner L, Ulfberg J, et al. Prevalence, severity and risk factors of restless legs syndrome in the general adult population in two Scandinavian countries. Sleep Med 6:307-312, 2005.
6. Lee KA, Zaffke ME, Baratte-Beebe K. Restless legs syndrome and sleep disturbance during pregnancy: the role of folate and iron. J Womens Health Gend Based Med 10:335-341, 2001.
7. Merlino G, Piani A, Dolso P, et al. Sleep disorders in patients with end-stage renal disease undergoing dialysis therapy. Nephrol Dial Transplant 21:184-190, 2006.
8. Manconi M, Govoni V, De Vito A, et al. Restless legs syndrome and pregnancy. Neurology 63:1065-1069, 2004.
9. Manconi M, Govoni V, De Vito A, et al. Pregnancy as a risk factor for restless legs syndrome. Sleep Med 5:305-308, 2004.
10. Manconi M, Ferini-Strambi L. Restless legs syndrome among pregnant women. Sleep 27:350; author reply 351, 2004.
11. Phillips B, Young T, Finn L, asher K, Hening WA, Purvis C. Epidemiology of restless legs symptoms in adults. Arch Intern Med 160:2137-41, 2000.
12. Comella CL. Restless Legs syndrome: Treatment with dopaminergic agents. Neurology 58:S87-S92, 2002.
13. Chesson AL, Wise M, Davila D, et al. Practice parameters for the treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Report. Standards of Practice Committee of the American Academy of Sleep Medicine. Sleep 22:961-8, 1999.
14. Hening W, Allen R, Earley C, et al. The treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Review. Sleep 22:970-99, 1999.
15. Allen R, Picchietti D, Hening W, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. Sleep Med 4:101-119, 2003.
16. Basseti CL, Mauerhofer D, Gugger M, et al. Restless legs syndrome:a clinical study of 55 patients. Eur Neurol 45:67-74, 2001.
17. Earley C. Restless Legs Syndrome. The New England Journal of Medicine 348:2103-2109, 2003.
18. Ekbom K. Restless legs: a clinical study. Acta Med Scand Suppl 158:1-123, 1945.
19. Gamaldo C, Earley C. Restless Legs Syndrome: A clinical update. Chest 130;1596-1604, 2006.
20. Hening W, Allen R, Washburn M, et al. The four diagnostic criteria for restless legs syndrome are unable to exclude confounding conditions ("mimics"). Sleep Med doi:10.1016/j.sleep.2008.09.015, 2009.
21. Benes H, Walters A, Allen R, et al. Definition of restless legs syndrome, how to diagnose it, and how to differentiate it from RLS mimics. Movement Disorders 22:S401-S408, 2007.
22. Salas R, Gamaldo C, Allen R, et al. Quiescegenic nocturnal dyskinesia: A restless legs syndrome (RLS) variant or a new syndrome? Sleep Medicine 10:394-397, 2008.
23. Allen RP, Earley CJ. Defining the phenotype of the restless legs syndrome (RLS) using age-of-symptom onset. Sleep Med 1:11-19, 2000.
24. Allen RP, Earley CJ. Restless legs syndrome: a review of clinical and pathophysiologic features. J Clin Neurophysiol 18(2):128-147, 2001.
25. Picchietti D, Winkelman JW. Restless legs syndrome, periodic limb movements in sleep, and depression. Sleep 28(7):891-8, 2005.
26. Ulfberg J, Nystrom B, Carter N, Edling C. Prevalence of restless legs syndrome among men aged 18 to 64 years: an association with somatic disease and neuropsychiatric symptoms. Mov Disord 16(6):1159-63, 2001.
27. McCrink L, Allen RP, Wolowacz S, Sherrill B, Connoly M, Kirsch J. Predictors of health-related quality of life in sufferers with restless legs syndrome: a multi-national study. Sleep Med 8(1):73-83, 2007.
28. Winkelman J, Shahar E, Sharief I, Gottlieb D. Association of restless legs syndrome and cardiovascular disease in the Sleep Heart Health Study. Neurology 70:35-42, 2008.
29. Allen RP, Walters A, Montplaisi J, Hening W, Myers A, Bell TF, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 165(11):1286-92, 2005.
30. Abetz L, Allen R, Follet A, Washburn T, Earley C, Kirsch J, et al. Evaluating the quality of life of patients with restless legs syndrome. Clin Therap 26(6):925-35, 2004.
31. Saletu M, Anderer P, Saletu B, Lindeck-Pozza L, Hauer C, Saletu-Zyhlarz G. EEG mapping in patients with restless legs syndrome as compared with normal controls. Psychiatry Res 115(1-2):49-61, 2002.
32. Gamaldo C, Benbrook A, Allen R, Oguntimein O, Earley C. Evaluating daytime alertness in individuals with Restless legs syndrome (RLS) compared to sleep restricted controls. Sleep Med 10:134-138, 2009.
33. Gamaldo C, Benbrook A, Allen R, Oguntimein O, Earley C. A further evaluation of the cognitive deficits associated with restless legs syndrome (RLS). Sleep Med 9:500-505, 2008.
34. Ekbom KA. Restless legs syndrome. Neurology 10:868-73, 1960.
35. Allen RP, Barker PB, Wehrl F, et al. MRI measurement of brain iron in patients with restless legs syndrome. Neurology 56:263-265, 2001.
36. Gelman N, Gorell JM, Barker PB, et al. MR Imaging of human brain at 3.0 T: preliminary report on transverse relaxation rates and relation to estimated iron content. Radiology 210:759-767, 1999.
37. Conner JR, Wang XS, Patton SM, et al. Decreased transferring receptor expression by neuromelanin cells in restless legs syndrome. Neurology 62:1563-1567, 2004.
38. Norlander NB. Therapy in restless legs. Acta Med Scand 145:453-7, 1953.
39. O'Keefe ST, Noel J, Lavan JN. Restless legs syndrome in the elderly. Postgrad Med J 69:701-3, 1993.
40. O'Keefe ST, Gavin K, Lavan JN. Iron status and restless legs syndrome in the elderly. Age Ageing 23:200-3, 1994.
41. Sun ER, Chen CA, Ho G, Earley CJ, Allen RP. Iron and the restless legs syndrome. Sleep 21:371-7, 1998.
42. Hening WA, Allen RP, Earley CJ, et al. An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep 27:560-583, 2004.
43. Wetter TC, Stiasny K, Winkelman J, et al. A randomized controlled study of pergolide in patients with restless legs syndrome. Neurology 52:944-50, 1999.
44. Montplaisir J, Nicolas A, Denesle R, Gomez-Mancilla B. Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology 52:938-43, 1999.
45. Allen RP, Picchitti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology: a report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 4:101-119, 2003.
46. Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 19:205-213, 1996.
47. Garcia-Borreguero D. Augmentation: understanding a key feature of RLS. Sleep Med 5:5-6, 2004.
48. Salas R, Allen R, Earley CJ, Gamaldo, C. Drug Hoarding: A case of atypical dopamine dysregulation syndrome in a RLS patient. Mov Disord 24:627-28, 2009.
49. Zanettini R, Antonini A, Gatto G, Gentile R, et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. NEJM 356(1):39-46, 2007.
50. Schade R, Andersohn F, Suissa S, Haverkamp W, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. NEJM 356(1):29-38, 2007.
51. Trenkwalder C, Benes H, Poewe W, Oertel WH, et al. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomized, double-blind, placebo-controlled trial. Lancet Neurol 7(7):595-604, 2008.
52. Walters AS. Review of receptor agonist and antagonist studies relevant to the opiate system in restless legs syndrome. Sleep Med 3:301-304, 2002.
53. Walters AS, Winkelmann J, Trenkwalder C, et al. Long-term follow-up on restless legs syndrome patients treated with opioids. Mov Disord 16:1105-1109, 2001.
54. Happe S, Klosch G, Saletu B, et al. Treatment of idiopathic restless legs syndrome (RLS) with gabapentin. Neurology 57:1717-1719, 2001.
55. Garcia-Borreguero D, Larrosa O, de a Llave Y, et al. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology 59:1573-1579, 2002.
56. Adler CH. Treatment of restless legs syndrome with gabapentin. Clin Neuropharmacol 20:148-151, 1997.
57. Mellick GA, Mellick LB. Management of restless legs syndrome with gabapentin (neurontin). Sleep 19:224-226, 1996.
58. Staedt J, Stoppe G, Riemann H, et al. Lamotrigine in the treatment of nocturnal myoclonus syndrome (NMS): two case reports. J Neural Transm 103:355-361, 1996.
59. Youssef EA, Wagner ML, Martinez JO, et al. Pilot trial of lamotrigine in the restless legs syndrome [letter]. Sleep Med 6:89, 2005.
60. Sommer M et al. Pregabalin in restless legs syndrome with and without neuropathic pain. Acta Neurol Scand 115(5):347-50, 2007.
61. Garcia-Borreguero. 61st AAN Meeting.
62. Montplaisir J, Boucher S, Poirer G, et al. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord 12:61-65, 1997.
63. Ondo W, Jankovic J. Restless legs syndrome: clinicoetiologic correlates. Neurology 47:1435-1441, 1996.
64. Allen RP, Earley CJ. Defining the phenotype of restless legs syndrome (RLS) using age-of-symptom-onset. Sleep Med 1:11-19, 2000.
65. Polydefkis M, Allen RP, Hauer P, Earley CJ, Griffin JW, McArthur JC. Subclinical sensory neuropathy in late-onset restless legs syndrome. Neurology 55:1115-21, 2000.
66. Bonati MT, Ferini-Strambi L, Aridon P, et al. Autosomal dominant restless legs syndrome maps on chromosome 14q. Brain 126:1485-1492, 2003.
67. Chen S, Ondo WG, Rao S, et al. Genomewide linkage scan identifies a novel susceptibility locus for restless legs syndrome on chromosome 9p. Am J Hum Genet 74:876-885, 2004.
68. Winkelman J, Lichtner P, Putz B, et al. Evidence for further genetic locus heterogeneity and confirmation of RLS-1 in restless legs syndrome. Mov Disord 21:28-33, 2006.
69. Stefansson H, Rye D, Hicks A, Petursson H, et al. A genetic risk factor for periodic limb movements in sleep. NEJM 357:639-647, 2007.
70. Pantaleo N, Hening W, Allen R, Earley C. Pregnancy accounts for most of the gender difference in prevalence of familial RLS. Sleep 2009; in press.
71. Picchietti D, Allen RP, Walters AS, Davidson JE, Myers A, Ferini-Strambi L. Restless legs syndrome: prevalence and impact in children and adolescents--the Peds REST study. Pediatrics 120(2):253-66, 2007.
72. Walters A. Is there a subpopulation of children with growing pains who really have restless legs syndrome? A review of the literature. Sleep Med 3:93-98, 2002.
73. Rajaram SS, Walters AS, England SJ, et al. Some children with growing pains may actually have restless legs syndrome. Sleep 27:767-773, 2004.
74. Mindell JA, Owens JA. A Clinical Guide to Pediatric Sleep: Diagnosis and Management of Sleep Problems. Philadelphia, PA: Lippincott Williams & Wilkins 2003.
75. Daviss WB, Perel JM, Birmaher B, et al. Steady-state clinical pharmacokinetics of bupropion extended-release in youths. J Am Acad Child Adolesc Psychiatry 45(12):1503-9, 2006.
76. Monuteaux MC, Spencer TJ, Faraone SV, Wilson AM, Biederman J. A randomized, placebo-controlled clinical trial of bupropion for the prevention of smoking in children and adolescents with attention- deficit/hyperactivity disorder. J Clin Psychiatry 68(7):1094-101, 2007.
77. Stewart JJ, Berkel HJ, Parish RC, et al. Single-dose pharmacokinetics of bupropion in adolescents: effects of smoking status and gender. J Clin Pharmacol 41(7):770-8, 2001.
78. Walters A, Rye D. Review of the relationship of restless legs syndrome and periodic limb movements in sleep to hypertension, heart disease, and stroke. Sleep Med 32:589-597, 2009.
79. Salas R. Long-term Treatment of RLS: augmentation, compulsive behaviors, and sleep-disordered breathing. 23rd Annual meeting of Associated Professional Sleep Societies, June 2009.
80. Evans A, Strafella A, Weintraub D, Stacy M. Impulsive and compulsive behaviors in Parkinson's disease. Mov Disord 2009; published advance online.
81. Salas R, Allen R, Earley C, Gamaldo C. A case of compulsive behaviors observed in a restless legs syndrome patient treated with a dopamine agonist. Sleep 5:587-88, 2009.
82. FDA Complete Response Letter Insists UCB Must Fix Neupro's Delivery Problems Before Market Relaunch. Dec 19, 2008. www.globalinsight.com/SDA/SDADetail15366.htm.
83. Neupro(R) (rotigotine Transdermal Patch) can now be prescribed to all patients with idiopathic Parkinson's disease in Europe. June 30, 2009. www.medicalnewstoday.com/articles/155718.php.
84. Stringer J, Welsh C, Tommasello A. Methadone-associated Q-T interval prolongation and torsades de pointes. American Journal of Health-System Pharmacy 9:825-833, 2009.
85. Berger K, Luedemann J, Trenkwalder C, John U, Kessler C. Sex and the risk of restless legs syndrome in the general population. Arch Intern Med 164(2):196-202, 2004.
86. Oner P, Dirik EB, Taner Y, Caykoylu A, Anlar O. Association between low serum ferritin and restless legs syndrome in patients with attention deficit hyperactivity disorder. Tohoku J Exp Med 213(3):269-76, 2007.
87. Hening WA, Allen RP, Washburn M, Lesage S, Earley CJ. Validation of the Hopkins telephone diagnostic interview for restless legs syndrome. Sleep Med 9(3):283-9, 2008.
88. Ferri R, Manconi M, Lanuzza B, et al. Age-related changes in periodic leg movements during sleep in patients with restless legs syndrome. Sleep Med 9(7):790-8, 2008.
89. Wang J, O'Reilly B, Venkataraman R, Mysliwiec V, Mysliwiec A. Efficacy of oral iron in patients with restless legs syndrome and a low-normal ferritin: A randomized, double-blind, placebo-controlled study, Sleep Med advance print online, 2009.
90. Grote L, Leissner L, Hedner J, Ulfberg J. A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Mov Disord 24(10):1445-52, 2009.
91. L Abetz et al. Evaluating the quality of life of patients with restless legs syndrome. Clinical Therapeutics 26:925-935, 2004.
92. Salas RE, Allen RP, Earley CJ, Gamaldo CE. A case of compulsive behaviors observed in a RLS patient treated with a dopamine agonist. Sleep 2009.

 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618